EOCN
Galmed Pharmaceuticals Ltd.
There isn't enough reported data to score EOCN yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EOCN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
EOCN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EOCN PE Valuation
EOCN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EOCN Forward outlook
There aren't enough analyst estimates for EOCN to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EOCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2023 | -$240.00 | +$782.40 |
| Q4 2022 | -$1,022.40 | +$878.40 |
| Q4 2021 | -$1,900.80 | +$50.81 |
| Q4 2020 | -$1,951.61 | -$555.87 |
| Q2 2020 | -$1,661.92 | -$768.77 |
| Q4 2019 | -$1,395.74 | -$535.77 |
| Q2 2019 | -$893.15 | +$339.67 |
| Q4 2018 | -$859.97 | +$575.82 |
EOCN has the edge over HIMS in the latest year-over-year earnings comparison.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EOCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2018 | $1.5M | +174% |
| Q2 2018 | $538K | 0% |
| Q4 2017 | $547K | +17% |
HIMS has the edge over EOCN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2018 | -306% | +3302 points |
| Q2 2018 | -965% | N/A |
| Q4 2017 | -1178% | N/A |
| Q2 2017 | -1088% | N/A |
| Q4 2016 | -3607% | N/A |
EOCN's operating margin was −306% last quarter, up 3301 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over EOCN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
EOCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2022 | -$18.5M | +$14.4M |
| Q2 2022 | -$11.4M | +$5.6M |
| Q4 2021 | -$32.9M | -$19.4M |
| Q2 2021 | -$16.9M | -$4.1M |
| Q4 2020 | -$13.5M | -$5.5M |
| Q2 2020 | -$12.8M | -$5.8M |
| Q4 2019 | -$7.9M | -$3.7M |
| Q2 2019 | -$7M | -$2.1M |
EOCN has burned cash in almost every quarter: −$80M over the past year, against −$41M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
EOCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +65% | +350K shares |
| 1 year | +1351% | +828K shares |
| 3 years | +5951% | +874K shares |
| 5 years | +11429% | +881K shares |
EOCN has 888,762 diluted shares, up 1351% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EOCN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EOCN Net Leverage
EOCN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
EOCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 16.2 | Oversold |
EOCN's weekly RSI is 31 (neutral) and its Stochastic is 16 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EOCN PE vs Healthcare Sector
EOCN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EOCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.11 | 23% below |
| 20 week MA | $3.80 | 37% below |
| 50 week MA | $4.86 | 51% below |
| 100 week MA | $9.57 | 75% below |
| 200 week MA | $94.9 | 97% below |
EOCN is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EOCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8,222.4 | $5,184.0 | -37% |
| 2021 | $5,184.0 | $2,923.2 | -44% |
| 2022 | $2,923.2 | $774.3 | -74% |
| 2023 | $774.3 | $43.7 | -94% |
| 2024 | $43.7 | $25.0 | -43% |
| 2025 | $25.0 | $6.92 | -72% |
| 2026 YTD | $6.92 | $2.39 | -65% |
EOCN has finished every year since 2020 lower, and it's down 65% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over EOCN on returns for 2026, with the stronger performance.